Korro Bio Doses First Patients in Phase 1/2 Trial for KRRO-121
Korro Bio has dosed its first cohort in a Phase 1/2 trial of KRRO-121, an RNA-editing therapy targeting hyperammonemia in rare metabolic disorders.
Cambridge, Mass.-based Korro Bio (Nasdaq: KRRO) announced Monday that the first cohort of participants has received doses of KRRO-121 in the company's Phase 1/2 clinical trial, known as ANCHOR, marking an early but significant milestone for the clinical-stage biopharmaceutical firm.
KRRO-121 is a GalNAc-conjugated RNA-editing oligonucleotide designed to treat hyperammonemia — a dangerous buildup of ammonia in the blood — in patients diagnosed with urea cycle disorders (UCDs) and hepatic encephalopathy (HE), two serious conditions with limited therapeutic options.
Read more Epcoritamab Plus R-CHOP Improves Survival in Lymphoma Trial →
The experimental therapy is built on Korro's proprietary OPERA platform, which stands for oligonucleotide promoted editing of RNA. The approach seeks to correct disease-causing errors at the RNA level without permanently altering DNA, a distinction the company says could offer a differentiated safety and flexibility profile compared with DNA-editing techniques.
Urea cycle disorders are inherited enzyme deficiencies that impair the body's ability to process nitrogen, while hepatic encephalopathy results from liver dysfunction that allows toxic ammonia levels to accumulate, causing neurological complications. Both conditions represent significant unmet medical needs, particularly in patient populations where current treatments fail to adequately control ammonia levels.
The Phase 1/2 ANCHOR trial represents Korro Bio's first clinical test of KRRO-121 in human participants. The company has not yet disclosed trial enrollment targets, dosing schedules, or expected timelines for interim data readouts. Continue reading at GlobeNewswire - Industry News on Financial Services.
